This company listing is no longer active
NMTR Stock Overview
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
9 Meters Biopharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.20 |
| 52 Week High | US$6.56 |
| 52 Week Low | US$0.18 |
| Beta | 1.48 |
| 11 Month Change | -72.75% |
| 3 Month Change | -85.45% |
| 1 Year Change | -96.00% |
| 33 Year Change | -98.32% |
| 5 Year Change | -99.85% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
9 Meters Biopharma to execute 1-for-20 reverse stock split
Oct 179 Meters Biopharma GAAP EPS of -$0.04 in-line
Aug 159 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome
Jun 149 Meters drug effective in treating rare COVID-19 complication in children
May 269 Meters Bio gains 5% on Adage Capital stake disclosure
Dec 299 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications
Dec 219 Meters Bio launches equity offering
Dec 11Shareholder Returns
| NMTR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -71.1% | 1.6% | 2.2% |
| 1Y | -96.0% | 9.9% | 31.6% |
Return vs Industry: NMTR underperformed the US Pharmaceuticals industry which returned -1.3% over the past year.
Return vs Market: NMTR underperformed the US Market which returned 16.1% over the past year.
Price Volatility
| NMTR volatility | |
|---|---|
| NMTR Average Weekly Movement | 22.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NMTR's share price has been volatile over the past 3 months.
Volatility Over Time: NMTR's weekly volatility has increased from 17% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 10 | Bethany Sensenig | www.9meters.com |
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease.
9 Meters Biopharma, Inc. Fundamentals Summary
| NMTR fundamental statistics | |
|---|---|
| Market cap | US$2.82m |
| Earnings (TTM) | -US$46.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs NMTR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NMTR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$46.28m |
| Earnings | -US$46.28m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -80.5% |
How did NMTR perform over the long term?
See historical performance and comparison